Humanigen Inc

Humanigen — Kalobios Pharmaceuticals — Investor Presentation (August 2016)

23 slides from Humanigen's investor presentation, Aug 31, 2016

  1. Slide 1: KaloBios Corporate Overview August 2016

    KaloBios Corporate Overview August 2016 Corporate Overview 1

  2. Slide 2: Forward-Looking Statements

    Forward - Looking Statements This presentation contains forward - looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward - looking statements reflect management’s current knowledge, assumptions, judgment and expectations regard

  3. Slide 3: KaloBios Value Model

    KaloBios Value Model Punching above weight with high - performance talent Reorient around specialty assets with various paths for significant commercial return – standalone commercial value, partnering and/or Priority Review Vouchers Reposition and drive pipeline to benefit from regulatory incentive

  4. Slide 4: History

    History • San Francisco R&D company, monoclonal antibody platform • Funding dead - end, winding down Oct 2015 , market cap < $ 4 MM • Martin Shkreli investment in late Nov 2015 • Shkreli arrest/indictment and Chapter 11 filing Dec 2015 • D elisted from NASDAQ Jan 2016 • Two new Board members Jan 201

  5. Slide 5: Execution Mindset

    Execution Mindset • Emerged from bankruptcy six months after declaring Chapter 11 – Successfully overcame multiple complex obstacles and defies predictions that it will either go into Chapter 7 or take years to emerge – Resolved all outstanding lawsuits • E xecuted deal for key product and raised $1

  6. Slide 6: Right Vision, Right People

    Right Vision, Right People • “Rising from the ashes” - new company, new strategy, new vision • Neglected and rare diseases with high unmet need and pediatric possibilities • Clear, focused, differentiated vision : x Strategy based on leveraging existing FDA regulatory incentives x Highly focused on

  7. Slide 7: Leadership

    Leadership Cameron Durrant , MD, MBA - Chairman and CEO • Senior pharmaceutical and biotech exec, turnaround specialist • Senior exec roles at global blue - chip pharma companies ; experience as Exec Chairman, CEO and CFO ; CEO roles at three specialty pharma groups • Expertise in anti - infectives

  8. Slide 8: Leadership

    Leadership Kip Witter, MBA, CPA - Interim Chief Financial Officer • Senior Consultant with The Brenner Group LLC, a financial consultancy group • CFO, Interim CFO, Secretary and Principal Accounting Officer roles • Board member of several privately held companies Dave Tousley, MBA, CPA - Consultant

  9. Slide 9: Board of Directors

    Board of Directors Cameron Durrant , MD, MBA • Chairman Ronald Barliant, JD • Of Counsel at Goldberg Kohn, extensive experience representing debtors and creditors in complex bankruptcy cases • United States bankruptcy judge for the Northern District of Illinois 1988 to 2002 Dale Chappell, MD, MBA •

  10. Slide 10: Strategy

    10 Corporate Overview Strategy Develop specialty products with strong societal, market and investor interest Utilize existing FDA regulatory incentives Advance medicines for neglected and rare diseases through innovative business models

  11. Slide 11: Priority Review Vouchers (PRVs)

    11 Corporate Overview Priority Review Vouchers (PRVs) • Two PRV programs • Neglected Tropical Disease (NTD) • Rare Pediatric Disease (RPD) • Incentivizes sponsors to bring medicines through FDA approval to U . S . patients • 10 vouchers awarded, 6 have been sold • Highest disclosed sale price of $ 3

  12. Slide 12: Disclosed PRV Sale Prices

    Disclosed PRV Sale Prices 12 Corporate Overview Publicly disclosed PRV sale prices as of August 1 , 2016 . D oes not include undisclosed , private transaction between Wellstat Therapeutics and AstraZeneca ( Sep 2015 ) or currently undisclosed Gilead PRV purchase (Jul 2016 ) . Drug Approval Date PRV

  13. Slide 13: KaloBios PRV Approach

    13 Corporate Overview KaloBios PRV Approach • KaloBios is not a PRV - only company • PRVs are an important incentive for developing drugs for conditions that other companies may have neglected . Seeking them is consistent with our strategy of leveraging existing regulatory incentives • Benznidazole

  14. Slide 14: Responsible Pricing Model

    Responsible Pricing Model • Strategic initiative to transform company and build a sustainable platform to execute strategy • Affordable for patients and payers whilst delivering a reasonable return for the company • Collaborate with key stakeholders on what constitutes a reasonable return • Publicly

  15. Slide 15: Current Pipeline

    Current Pipeline 15 Corporate Overview Pre - clin Phase I Phase II Phase III NDA/BLA Benznidazole Chagas disease Anti - infective Lenzilumab CMML Anti - GM - CSF mAb Lenzilumab *JMML ( peds ) – dependent on interim data in CMML Anti - GM - CSF mAb Ifabotuzumab *Solid ( peds ) tumors Anti - EphA3 mAb

  16. Slide 16: Chagas Disease

    Chagas Disease 16 Corporate Overview • American trypanosomiasis , also known as Chagas disease • Infectious disease caused by protozoan parasite Trypansosoma cruzi Spread by contact with feces of infected triatomine bugs (“kissing bugs”) • Complications include cardiovascular, gastrointestinal, neur

  17. Slide 17: Benznidazole

    Benznidazole • Orally active, nitroimidazole derivative for the treatment of Chagas disease • Currently approved in several Latin American countries, not in the U.S. - only available from CDC • Current preferred treatment for Chagas • Chagas disease on FDA’s Neglected Tropical Disease list that woul

  18. Slide 18: Lenzilumab

    Lenzilumab • Favorable safety profile • Multiple phase 1 - 2 studies, no drug - related serious adverse events (>90 patients dosed) • Potential in CMML and JMML (both orphan conditions) • Potential Breakthrough Therapy designation • Potential for a PRV in JMML as a Rare Pediatric Disease 18 Corporat

  19. Slide 19: Lenzilumab Clinical Path

    Lenzilumab Clinical Path 19 Corporate Overview PHASE 1 - 2 DOSE ESCALATION AND EXPANSION • Initial dose finding (phase 1) in ~15 subjects • Enrollment period: 12 – 18 months • Phase 2 expansion upon level of activity observed • Expand to ~30 - 40 total subjects CMML JMML* DOSE ESCALATION STUDY: Dete

  20. Slide 20: Ifabotuzumab

    Ifabotuzumab • Prior clinical experience, Phase 1 study completed in hematologic malignancies, > 50 patients dosed • Potential in solid tumors, including rare pediatric tumors • RPD PRV potential if approved • Phase 0 /I bio - distribution study in rare solid tumors such as glioblastoma or other bra

  21. Slide 21: KaloBios Strategic Rationale

    Increases number of early investor value catalysts 21 Corporate Overview KaloBios Strategic Rationale Buys down regulatory risk: Potential to be Faster/Cheaper/Better 1. Expedited clinical development and regulatory pathway 2. Less costly clinical development due to speed, low patient numbers and re

  22. Slide 22: Summary and Potential Near-Term Value Catalysts

    Extinguished Shkreli stake per 8 - K Accelerate benznidazole program + FDA meeting Continue to enroll and accelerate lenzilumab Ph I Become current with financial filings Strengthen financial platform Summary • KaloBios is “rising from the ashes” • Unusual history creates a unique setting for transf

  23. Slide 23: Thank You

    www.kalobios.com Thank You Corporate Overview 23

Kalobios Pharmaceuticals — Investor Presentation (August 2016) on 6ix